Dashboard
Manage Tickers

ABOSAcumen Pharmaceuticals, Inc.

Nasdaq acumenpharm.com


$ 3.67 $ -0.08 (-2.14 %)    

Friday, 17-May-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 3.65
$ 3.69
$ 0.00 x 0
$ 0.00 x 0
$ 3.63 - $ 3.76
$ 1.81 - $ 11.31
79,239
na
218.31M
$ 0.67
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-26-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-27-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-28-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-acumen-pharmaceuticals-maintains-15-price-target
HC Wainwright & Co. Reiterates Buy on Acum...
05/15/2024 11:19:12

HC Wainwright & Co. analyst Andrew Fein reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $15 pri...

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
05/14/2024 12:06:42

acumen-pharmaceuticals-q1-2024-gaap-eps-025-beats-027-estimate
Acumen Pharmaceuticals Q1 2024 GAAP EPS $(...
05/14/2024 11:01:13

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate o...

acumen-pharmaceuticals-says-first-patient-dosed-in-altitude-ad-a-phase-2-clinical-trial-of-sabirnetug-in-early-alzheimers-disease
Acumen Pharmaceuticals Says First Patient ...
05/08/2024 12:28:21

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targ...

Core News & Articles
Watching Eledon Pharmaceuticals, Acumen Ph...
04/18/2024 15:41:59

https://blog.tipranks.com/these-2-strong-buy-penny-stocks-are-poised-for-over-300-gains-say-analysts/  

acumen-pharmaceuticals-presents-first-comprehensive-clinical-and-biomarker-data-for-sabirnetug-at-american-academy-of-neurology-2024-annual-meeting
Acumen Pharmaceuticals Presents First Comp...
04/16/2024 12:17:32

Presentation and poster include deeper data insights on sabirnetug safety profile, target engagement and fluid biomarker change...

acumen-pharmaceuticals-collaborates-with-lonza-covering-the-manufacture-of-sabirnetug-acu193-for-alzheimers-disease-for-clinical-development-and-commercialization-if-approved
Acumen Pharmaceuticals Collaborates With L...
04/04/2024 12:03:36

hc-wainwright--co-maintains-buy-on-acumen-pharmaceuticals-maintains-15-price-target
HC Wainwright & Co. Maintains Buy on Acume...
03/27/2024 13:22:02

HC Wainwright & Co. analyst Andrew Fein maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $15 pric...

acumen-pharmaceuticals-q4-eps-029-misses-026-estimate
Acumen Pharmaceuticals Q4 EPS $(0.29) Miss...
03/26/2024 13:28:09

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate...

acumen-pharmaceuticals-fy23-eps-108-down-from-106-yoy-cash-cash-equivalents-and-marketable-securities-3061m
Acumen Pharmaceuticals FY23 EPS $(1.08) Do...
03/26/2024 11:08:43

earnings-scheduled-for-march-26-2024
Earnings Scheduled For March 26, 2024
03/26/2024 08:47:27

Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on reve...

acumen-pharmaceuticalss-earnings-a-preview
Acumen Pharmaceuticals's Earnings: A Preview
03/25/2024 15:02:18

acumen-pharmaceuticals-to-present-deeper-insights-including-fluid-biomarker-data-for-sabirnetug-during-emerging-science-session-at-the-american-academy-of-neurology-annual-meeting
Acumen Pharmaceuticals To Present Deeper I...
03/21/2024 12:07:54

- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21, 2024 (...

acumen-pharmaceuticals-presents-sabirnetug-fluid-biomarker-target-engagement-analyses-from-phase-1-intercept-ad-study-in-early-alzheimers-at-adpd-2024-annual-meeting
Acumen Pharmaceuticals Presents Sabirnetug...
03/08/2024 13:57:48

Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug's downstream pharmacological effects in the...

acumen-pharmaceuticals-shares-are-trading-higher-after-the-company-presented-biomarker-data-from-the-acu193-phase-1-intercept-ad-trial-at-the-international-conference-on-alzheimers-and-parkinsons-diseases
Acumen Pharmaceuticals shares are trading ...
03/08/2024 13:52:30

acumen-pharmaceuticals-to-present-sabirnetug-fluid-biomarker-and-target-engagement-analyses-from-phase-1-intercept-ad-study-in-early-alzheimers-at-the-adpd-2024-annual-meeting
Acumen Pharmaceuticals To Present Sabirnet...
02/21/2024 13:24:53

-   Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD-   Poster...

acumen-pharmaceuticals-appointsf-james-doherty-as-president-and-chief-development-officer-effective-february-1-2024
Acumen Pharmaceuticals Appointsf James Doh...
02/01/2024 12:31:07

deutsche-bank-initiates-coverage-on-acumen-pharmaceuticals-with-buy-rating-announces-price-target-of-8
Deutsche Bank Initiates Coverage On Acumen...
12/12/2023 09:30:11

Deutsche Bank analyst Neena Bitritto-Garg initiates coverage on Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy rating and a...

acumen-pharmaceuticals-secures-500m-credit-facility-with-k2-healthventures
Acumen Pharmaceuticals Secures $50.0M Cred...
11/13/2023 12:08:29

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) ("Acumen" or the "Company"), a clinical-stage biopharmaceutical comp...

acumen-pharmaceuticals-q3-eps-024-vs-026-yoy-cash-balance-of-2827m-likely-to-support-current-clinical-and-operational-activities-into-the-second-half-of-2026
Acumen Pharmaceuticals Q3 EPS $(0.24) Vs $...
11/13/2023 12:04:27

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION